About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

At the moment the company generates 1M USD in revenues.

On its last earning announcement, the company reported a loss of -3.00$ per share.

The book value per share is 4.38$

Fulcrum Therapeutics, Inc. website

Create a solid portfolio with FULC

Add FULC to your portfolio and optimize it!


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
1M - -66M - -64M -3.00 - - 23M 4.38 -45M -1M -45M